Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters in patients with hepatorenal syndrome (HRS), including a Poster of Distinction, at The ...

The FDA has called for more research on this problem, with an emphasis on recruiting a more diverse group of patients into ...

Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on terlipressin in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI), at ...

Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With ...